EAU 2022 | Benefits of upfront staging with PSMA-PET in high-risk prostate cancer
Tobias Maurer, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany discusses evidence highlighting the superiority of PSMA-PET to conventional imaging techniques and the benefits of using PSMA-PET for the upfront staging of prostate cancer in high-risk patients. Specifically, Dr Maurer describes how PSMA-PET is particularly beneficial in staging certain subgroups of high-risk prostate cancer patients, such as those lacking elevated prostate-specific antigen (PSA) levels. This interview took place at the European Association of Urology (EAU) Meeting 2022.
Disclosures
Dr Maurer reports the following conflicts of interest:
Advisory roles: Advanced Accelerator Applications International S.A., Novartis, Telix, ROTOP Pharma, GEMoAb, Astellas, Blue Earth Diagnostics, ABX
Speaker roles for Bayer, Sanofi-Aventis, Astellas, Phillips
